NCT02525874 is a Phase 3 clinical trial of dimethyl fumarate in Multiple Sclerosis, Relapsing-Remitting, sponsored by Biogen.

Who is sponsoring NCT02525874?

NCT02525874 is sponsored by Biogen.

What drugs are being tested in NCT02525874?

Interventions in NCT02525874: dimethyl fumarate.

What condition does NCT02525874 study?

NCT02525874 studies Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis.

Is NCT02525874 still recruiting?

NCT02525874 is currently completed. Last updated 27 June 2019.

Are results published for NCT02525874?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-06-27 · How we verify

NCT02525874

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Completed Phase 3 Results posted Last updated 27 June 2019

What this trial tests

Phase 3 trial testing dimethyl fumarate in Multiple Sclerosis, Relapsing-Remitting in 218 participants. Completed in 23 April 2018.

Timeline

11 August 2015

Primary endpoint
24 April 2017

23 April 2018

Quick facts

Lead sponsor	Biogen
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	218
Start date	11 August 2015
Primary completion	24 April 2017
Estimated completion	23 April 2018
Sites	34 locations across Belgium, Poland, Lithuania, Bulgaria, Kuwait, United States, Turkey (Türkiye)

Drugs / interventions tested

dimethyl fumarate (DIMETHYL FUMARATE) — full drug profile →

Conditions studied

Multiple Sclerosis, Relapsing-Remitting — all drugs for Multiple Sclerosis, Relapsing-Remitting →
Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Biogen — full company profile →

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis, Relapsing-Remitting or Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T Cell, B Cell, Natural Killer Cell (TBNK) Primary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

Lymphocyte subsets include T cell, B cell and Natural killer (NK) cells.

B Cells: Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	235.9	± 168.88

B Cells: Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-18.8	± 89.71

B Cells: Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-48.2	± 122.20

B Cells: Change at Week 12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-65.9	± 128.53

B Cells: Change at Week 24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-76.5	± 140.33

B Cells: Change at Week 36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-70.1	± 104.80

B Cells: Change at Week 48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-60.7	± 115.26

NK Cells: Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	184.2	± 107.12

Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T-Cells Subsets Primary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

T-cells subsets includes Activated CD4+ T-cell, Activated CD8+ T-cell, Activated CD8+ T-cell \[CD38+\], Activated Th (T helper) 1 phenotype, Activated Th17 phenotype, Activated Th2-enriched phenotype, Activated CD4+ T-cell \[CD38+HLA-DR+\], Activated CD4+ T-cell \[HLA-DR+\], Activated CD8+ T-cell \[HLA-DR+\], Central Memory (CM) CD4+ T-cell \[CD45RA-CCR7+\], CM CD4+ T-cell \[CD45RA-CCR7+\], CM CD8+ T-cell \[CD45RA-CCR7+\], Effector CD4+ T-cell \[CD45RA+CCR7-\], Effector CD8+ T-cell \[CD45RA+CCR7-\], Effector Memory (EM) CD4+ T-cell \[CD45RA-CCR7-\], EM CD8+ T-cell \[CD45RA-CCR7-\], Effector Re

Activated CD4+ T-cell [CD38+]: Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	632.6	± 305.86

Activated CD4+ T-cell [CD38+]: Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	15.2	± 241.73

Activated CD4+ T-cell [CD38+]: Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-26.5	± 241.47

Activated CD4+ T-cell [CD38+]: Change at Week 12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-53.4	± 246.22

Activated CD4+ T-cell [CD38+]: Change at Week 24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-100.4	± 263.58

Activated CD4+ T-cell [CD38+]: Change at Week 36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-106.8	± 308.03

Activated CD4+ T-cell [CD38+]: Change at Week 48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-125.9	± 273.26

Activated CD8+ T-cell ([CD38+HLA-DR+]): Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	22.9	± 25.64

Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: B-Cell Subsets Primary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

B-cell subsets include CD10+ Transitional B cells, CD138+ Plasma Cells, Ig (Immunoglobulin) D+ Memory B cells \[non-class switched\], IgD- Memory B cells \[class switched\], Naïve B cells, Plasma Cells \[CD10-\], Transitional B-cells and Plasmablasts. Here, Change at week is represented as CW.

CD10+ Transitional B cells: Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	9.4	± 9.93

CD10+ Transitional B cells: Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-1.2	± 7.98

CD10+ Transitional B cells: Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.4	± 8.73

CD10+ Transitional B cells: Change at Week 12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.4	± 9.09

CD10+ Transitional B cells: Change at Week 24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	3.6	± 10.16

CD10+ Transitional B cells: Change at Week 36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	2.8	± 9.53

CD10+ Transitional B cells: Change at Week 48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	5.7	± 13.53

CD138+ Plasma Cells: Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	0.26	± 0.289

Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: Myeloid and Natural Killer (NK) Cells Primary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

Myeloid and natural killer cell subsets include CD56Bright NK cells, CD56Dim NK cells, Classical Monocytes, Myeloid dendritic cells, Non-classical Monocytes, Plasmacytoid dendritic cells, Total dendritic cells and Total monocytes \[CD14+\].

CD56Bright NK cells: Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	14.0	± 8.94

CD56Bright NK cells: Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	1.8	± 6.40

CD56Bright NK cells: Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	1.8	± 7.07

CD56Bright NK cells: Change at Week 12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	1.3	± 7.26

CD56Bright NK cells: Change at Week 24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	2.1	± 8.57

CD56Bright NK cells: Change at Week 36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	2.3	± 9.73

CD56Bright NK cells: Change at Week 48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	2.1	± 8.55

CD56Dim NK cells: Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	192.9	± 130.45

Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T-Cell Cytokines Primary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

T-cell cytokine subsets include IFN (interferon) g+ (% of CD4+ T cells), IFNg+ (% of CD8+ T cells), IFNg+ (% of memory CD4+ T cells), IFNg+ (% of memory CD8+ T cells), IL- (interleukin) 17A+/IFNg- (% of CD4+ T cells), IL-17A+/IFNg- (% of CD8+ T cells), IL-17A+/IFNg- (% of memory CD4+ T cells), IL-17A+/IFNg- (% of memory CD8+ T cells), IL-2+ (% of CD4+ T cells), IL-2+ (% of CD8+ T cells), IL-2+ (% of memory CD4+ T cells), IL-2+ (% of memory CD8+ T cells), IL-4+ (% of CD4+ T cells), IL-4+ (% of CD8+ T cells), IL-4+ (% of memory CD4+ T cells) and IL-4+ (% of memory CD8+ T cells). Here, Change at

IFNg+ (% of CD4+ T cells): Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	3.340	± 2.7365

IFNg+ (% of CD4+ T cells): Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	0.090	± 2.2350

IFNg+ (% of CD4+ T cells): Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.356	± 1.9676

IFNg+ (% of CD4+ T cells): Change at Week12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.729	± 2.1570

IFNg+ (% of CD4+ T cells): Change at Week24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-1.134	± 2.4239

IFNg+ (% of CD4+ T cells): Change at Week36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-1.511	± 2.5109

IFNg+ (% of CD4+ T cells): Change at Week48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-1.222	± 2.3513

IFNg+ (% of CD8+ T cells): Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	6.166	± 4.6199

Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: Very Late Antigen-4 (VLA-4/Lymphocyte Function-Associated Antigen-1 (LFA-1) Antigen Primary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

VLA-4/LFA-1 antigen subsets include CD11a+ (% of B cells), CD11a+ (% of T cells), CD11a+ (% of MNC), CD11a+ (% of dendritic cells \[CD11c++\]), CD11a+ (% of lymphocytes), CD11a+ (% of monocytes), CD11a+ (% of neutrophils), CD49d+ (% of B cells), CD49d+ (% of T cells), CD49d+ (% of MNC), CD49d+ (% of dendritic cells \[CD11c++\]), CD49d+ (% of lymphocytes), CD49d+ (% of monocytes) and CD49d+ (% of neutrophils).

CD11a+ (% of B cells): Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	99.33	± 2.106

CD11a+ (% of B cells): Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	0.34	± 2.497

CD11a+ (% of B cells): Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	0.44	± 2.203

CD11a+ (% of B cells): Change at Week 12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	0.17	± 2.534

CD11a+ (% of B cells): Change at Week 24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	0.19	± 2.549

CD11a+ (% of B cells): Change at Week 36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-1.43	± 11.406

CD11a+ (% of B cells): Change at Week 48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.14	± 7.751

CD11a+ (% of T cells): Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	99.90	± 0.312

Change From Baseline in Immunoglobulin A (IgA) up to 48 Weeks Secondary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	2116.5	± 910.47

Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-120.0	± 231.16

Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-112.8	± 243.28

Change at Week 12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-93.6	± 291.76

Change at Week 24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-101.5	± 324.27

Change at Week 36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-65.1	± 279.53

Change at Week 48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-94.9	± 291.25

Change From Baseline in Immunoglobulin M (IgM) up to 48 Weeks Secondary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	1330.1	± 705.92

Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-68.9	± 214.07

Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-23.2	± 208.48

Change at Week 12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-18.8	± 270.82

Change at Week 24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-36.9	± 293.14

Change at Week 36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-19.4	± 406.86

Change at Week 48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-96.8	± 236.48

Change From Baseline in Immunoglobulin G (IgG) up to 48 Weeks Secondary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	10.51	± 2.328

Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.77	± 1.039

Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.64	± 1.077

Change at Week 12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.44	± 1.187

Change at Week 24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.62	± 1.324

Change at Week 36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.36	± 1.025

Change at Week 48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.53	± 1.142

Change From Baseline in Immunoglobulin G (IgG) Subclasses up to 48 Weeks Secondary · Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

IgG Subclass 1: Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	542.9	± 152.87

IgG Subclass 1: Change at Week 4

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-29.2	± 68.22

IgG Subclass 1: Change at Week 8

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-28.5	± 71.46

IgG Subclass 1: Change at Week 12

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-14.8	± 79.07

IgG Subclass 1: Change at Week 24

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-3.0	± 78.80

IgG Subclass 1: Change at Week 36

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-23.1	± 61.73

IgG Subclass 1: Change at Week 48

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	-0.5	± 102.41

IgG Subclass 2: Baseline

Group	Value	95% CI
Dimethyl Fumarate (BG00012)	350.7	± 116.43

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 33 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Dimethyl Fumarate (BG00012)

Serious: 26/218 (12%)

Deaths: 0/218

Serious adverse events (16 terms)

Reaction	System	Dimethyl Fumarate (BG00012)
Multiple sclerosis relapse	Nervous system disorders	—
Acute myocardial infarction	Cardiac disorders	—
Iridocyclitis	Eye disorders	—
Non-cardiac chest pain	General disorders	—
Cholecystitis chronic	Hepatobiliary disorders	—
Cellulitis	Infections and infestations	—
Nasopharyngitis	Infections and infestations	—
Diabetes mellitus inadequate control	Metabolism and nutrition disorders	—
Diabetic ketoacidosis	Metabolism and nutrition disorders	—
Arthralgia	Musculoskeletal and connective tissue disorders	—
Breast cancer stage I	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—
Neurological decompensation	Nervous system disorders	—
Anembryonic gestation	Pregnancy, puerperium and perinatal conditions	—
Device malfunction	Product Issues	—
Nephrolithiasis	Renal and urinary disorders	—
Menorrhagia	Reproductive system and breast disorders	—

Other adverse events (20 terms — click to expand)

Reaction	System	Dimethyl Fumarate (BG00012)
Flushing	Vascular disorders	—
Multiple sclerosis relapse	Nervous system disorders	—
Nasopharyngitis	Infections and infestations	—
Diarrhoea	Gastrointestinal disorders	—
Upper respiratory tract infection	Infections and infestations	—
Fatigue	General disorders	—
Abdominal pain	Gastrointestinal disorders	—
Abdominal pain upper	Gastrointestinal disorders	—
Nausea	Gastrointestinal disorders	—
Pruritus	Skin and subcutaneous tissue disorders	—
Headache	Nervous system disorders	—
Arthralgia	Musculoskeletal and connective tissue disorders	—
Vomiting	Gastrointestinal disorders	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—
Lymphopenia	Blood and lymphatic system disorders	—
Lymphocyte count decreased	Investigations	—
Anxiety	Psychiatric disorders	—
Depression	Psychiatric disorders	—
Abdominal discomfort	Gastrointestinal disorders	—
Erythema	Skin and subcutaneous tissue disorders	—

Most-reported serious reactions: Multiple sclerosis relapse, Acute myocardial infarction, Iridocyclitis, Non-cardiac chest pain, Cholecystitis chronic, Cellulitis, Nasopharyngitis, Diabetes mellitus inadequate control.

Data from ClinicalTrials.gov NCT02525874 adverse events section.

Sponsor's own description

The primary objective of the study is to evaluate the effect of BG00012 on lymphocyte subset counts during the first year of treatment in subjects with relapsing-remitting multiple sclerosis (RRMS). A secondary objective is to evaluate the pharmacodynamic effect on absolute lymphocyte counts (ALCs) and immunoglobulins (Igs) during the first year of treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Induction of Cardiac Pathology: Endogenous versus Exogenous Nrf2 Upregulation.
Mathis BJ, Kato H, Hiramatsu Y. · · 2022 · cited 5× · PMID 36497112 · DOI 10.3390/cells11233855
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients.
Mao-Draayer Y, Bar-Or A, Balashov K, Foley J, et al · · 2025 · cited 4× · PMID 39570545 · DOI 10.1007/s12325-024-03047-w

Verify or expand the search:

Other trials of dimethyl fumarate

Trials testing the same drug.

NCT06850597 — Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's D · Phase 2 · recruiting
NCT02969304 — Study of Utilization Patterns of Dimethyl Fumarate in Germany · completed
NCT02555215 — Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) · Phase 3 · completed
NCT02471560 — Tecfidera and the Gut Microbiota · Phase 4 · completed
NCT02410200 — Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS · Phase 2 · completed

Other recruiting trials for Multiple Sclerosis, Relapsing-Remitting

Currently open trials in the same condition.

NCT06408259 — Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relap · Phase 3 · recruiting
NCT06569550 — Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis · NA · recruiting
NCT06389968 — Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis · NA · recruiting
NCT06345157 — ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients · active not recruiting
NCT06715436 — Multiple Sclerosis and the Effects of Ketogenic Diet Therapy · NA · recruiting

Other Biogen trials

Trials by the same sponsor.

NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
NCT07444450 — A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy · Phase 3 · not yet recruiting
NCT07444489 — A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants · Phase 3 · not yet recruiting
NCT07444476 — A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years Wit · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02525874 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biogen
Last refreshed: 27 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02525874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02525874

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (16 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of dimethyl fumarate

Other recruiting trials for Multiple Sclerosis, Relapsing-Remitting

Other Biogen trials

Verify against primary sources